Company Filing History:
Years Active: 2009
Title: Yong Li - Innovator in Targeted Alpha Therapy
Introduction
Yong Li is a prominent inventor based in Horstville, Australia. He has made significant contributions to the field of cancer therapy through his innovative work on radioimmunoconjugates. His research focuses on developing targeted alpha therapy, which has the potential to revolutionize cancer treatment.
Latest Patents
Yong Li holds a patent for "Radioimmunoconjugates for targeted alpha therapy." This invention involves a radioimmunoconjugate that comprises an alpha-emitter, such as Bi-213, linked to the monoclonal antibody C595. This technology is particularly effective in treating various types of cancer, including pancreatic, prostate, breast, and ovarian cancer.
Career Highlights
Yong Li is associated with the European Community, as represented by the European Commission. His work has garnered attention for its innovative approach to cancer treatment, showcasing his dedication to improving patient outcomes through advanced medical technologies.
Collaborations
Yong Li has collaborated with notable professionals in his field, including Barry John Allen and Syed Rizvi. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Yong Li's contributions to targeted alpha therapy exemplify the impact of innovation in the medical field. His work continues to inspire advancements in cancer treatment, highlighting the importance of research and collaboration in developing effective therapies.